Skip to content

The Impact of Exercise on the Performance of an Artificial Pancreas in Type 1 Diabetes and Impaired Awareness of Hypoglycaemia

Evaluation of the Impact of Exercise and Related Changes in Counter-Regulatory Hormones on the Performance of an Artificial Pancreas in Adults with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12618000070235
Acronym
None
Enrollment
12
Registered
2018-01-17
Start date
2018-01-17
Completion date
2018-09-17
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

A hybrid closed-loop (HCL) system or ‘artificial pancreas’ provides automated control of basal insulin delivery, with ongoing requirements for manual boluses of insulin for meals. These systems offer the potential to reduce significant glucose excursions outside of a healthy glucose range compared with current available therapies. Some people with type 1 diabetes have difficulty recognising when they are having a hypoglycaemic episode, which is called hypoglycaemic unawareness. This often leads to fear of exercise due to the unpredictable changes in glucose levels that can occur with exercise. It is known that short intense bursts of exercise (anaerobic exercise) may initially increase glucose levels, whilst less intense exercise (aerobic exercise) tends to reduce glucose levels. This study aims to collect information on how well the HCL system controls glucose levels in people with type 1 diabetes and hypoglycaemia unawareness when they undertake anaerobic and aerobic exercise. Outcomes of interest will include time spent in healthy glucose range, and time spent in hypoglycaemic range. Insulin and counter-regulatory hormones will also be measured providing insights into changes in glucose levels with exercise in this group of people.

Interventions

This is a two-stage randomised crossover study involving adults with type 1 diabetes and impaired awareness of hypoglycaemia who are established on insulin pump therapy and have glucose sensing experience. The study aims to examine the performance of an ‘artificial pancreas’ or hybrid closed-loop (HCL) insulin delivery system challenged by high intensity intermittent exercise (HIIE) and moderate intensity exercise (MIE) in people with type 1 diabetes and impaired awareness of hypoglycaemia. Pr

This is a two-stage randomised crossover study involving adults with type 1 diabetes and impaired awareness of hypoglycaemia who are established on insulin pump therapy and have glucose sensing experience. The study aims to examine the performance of an ‘artificial pancreas’ or hybrid closed-loop (HCL) insulin delivery system challenged by high intensity intermittent exercise (HIIE) and moderate intensity exercise (MIE) in people with type 1 diabetes and impaired awareness of hypoglycaemia. Previous studies have shown that the HCL system is safe for people with type 1 diabetes undertaking HIIE (anaerobic) and MIE (aerobic). However, this has not been assessed in the group with impaired awareness of hypoglycaemia. Potential participants will be identified using a validated questionnaire (Gold questionnaire) to assess their degree of hypoglycaemia unawareness. A Gold score of 4 or greater implies impaired awareness of hypoglycaemia. All participants will use the HCL system for the study duration. Education specific to the HCL study system will be provided face-to-face by an experienced study doctor and a diabetes nurse educator, and will be tailored to each participant’s prior knowledge. Participants will also be provided educational material and resources, including a user guide booklet for the investigational HCL system. The HCL system comprises a glucose sensor coupled with an insulin pump containing a computerised automated insulin delivery algorithm. Glucose sensor information is transmitted to the insulin pump, and the dose of insulin is calculated by the algorithm and delivered every 5 minutes to account for basal insulin requirements. Participant initiated bolus insulin doses are still required for meals. Following clinical assessment, each participant will undergo cardiopulmonary testing to determine their maximal amount of oxygen consumed during exercise (VO2 max as ml/kg/min), maximal exercise capacity (Watts) and anaerobic threshold. All participants will undertake the HIIE and MIE stages in random order. All exercise testing will be closely supervised at all times by both a qualified study doctor and a nurse with dual training in research coordination and diabetes education. Approximately 1 week after activation of the HCL system, participants will undertake their first exercise stage. They will then return ~1 week later to undertake the alternate exercise regimen. All exercise testing will be conducted in the late morning, at least 4 hours after breakfast is consumed. The MIE protocol will be conducted on a stationary bicycle with 5 minutes of warm-up, followed by 40 minutes of steady-state exercise at 70% of anaerobic threshold. The HIIE protocol is high intensity interval training with 5 minutes of warm-up, then 6 repetitions of 4 minutes of exercise at an intensity halfway between their anaerobic threshold and maximal intensity, followed by 2 minutes of rest (an additional 4 minutes rest will be provided between the 3rd and 4th repetitions). On the morning of the exercise study days, participants will have an early morning light breakfast (40g of carbohydrate), preceded by an insulin bolus via their own pump to account for the carbohydrate of the meal. The participants will commence their exercise program ~2 hours after arrival at the Clinical Trial Centre, at which time the ‘exercise mode’ of the HCL system will be activated. Venous blood samples will be collected at 15 minute intervals from 1 hour prior to exercise until 2 hours after exercise completion to assess insulin and counter-regulatory hormones. Participants will return one week following the second exercise stage to return study devices and resume their usual insulin delivery system.

Sponsors

St Vincent's Hospital
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Type 1 diabetes 2. Established on insulin pump therapy for at least 6 months 3. Sensor experience 4. HbA1c < 10.0% 5. GOLD score >=4 6. Ability to perform exercise as per protocol

Exclusion criteria

1. Chronic kidney disease (eGFR <45mL/min/1.73m2) 2. Requiring > 150 units of insulin/day 3. Diabetic ketoacidosis within the past 4 weeks 4. Use of non-insulin glucose-lowering agent in the past 3 months 5. Steroid use (oral or injected) within past 3 months 6. Pregnancy 7. Ischaemic heart disease or peripheral vascular disease precluding exercise

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026